Trials / Completed
CompletedNCT00036244
Synthetic Human Secretin in Children With Autism
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Repligen Corporation · Industry
- Sex
- All
- Age
- 32 Months – 59 Months
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RG1068 (Synthetic Human Secretin) |
Timeline
- Start date
- 2002-04-01
- Completion
- 2004-01-01
- First posted
- 2002-05-09
- Last updated
- 2005-08-05
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00036244. Inclusion in this directory is not an endorsement.